Cosmetic cross-reference Noindex: medium evidence

608-25-3

CAS 608-25-3

608-25-3 (CAS 608-25-3) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
608-25-3
CAS Number
608-25-3
UNII
32W7044A3T
InChIKey
ZTMADXFOCUXMJE-UHFFFAOYSA-N
ChEMBL ID
CHEMBL2332773
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 608-25-3 used for in pharmaceutical contexts?

608-25-3 (CAS 608-25-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 608-25-3?

No adverse-event association or SIDER side-effect rows are rendered for 608-25-3 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 608-25-3 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for 2-Methylresorcinol ⭐ (Most extensively assessed) with EU status "prohibited".

What clinical phase is 608-25-3 in?

No phase 1-4 clinical development badge is rendered for 608-25-3 because the matched compound identifier rows do not contain a max-phase value.